InVivoMAb anti-human CD47
Clone Catalog # Category
B6.H12 BE0019-1 InVivoMab Antibodies
$300 - 3080

The B6H12 monoclonal antibody reacts with human CD47 otherwise known as integrin-associated protein (IAP), and neurophilin. CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is a receptor for thrombospondin-1 (TSP-1), a secreted glycoprotein that plays a role in vascular development and angiogenesis. CD47 Is has been found to be overexpressed in many different tumor cells. Because of this, anti-CD47 monoclonal antibodies have been proposed and studied as a therapeutic treatment for human cancers. The B6H12 antibody has been shown to neutralize CD47 and inhibit the growth of hepatocellular carcinoma cells in vitro.


Mouse IgG1

Recomended Isotype Control(s) InVivoMAb mouse IgG1 isotype control, unknown specificity
Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer

Intact CD47 purified from placenta

Reported Applications
  • in vitro CD47 neutralization
  • in vivo CD47 neutralization in human tumor xenograft models or humanized mice
  • Flow cytometry
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
  • >95%
  • Determined by SDS-PAGE
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives

0.2 μM filtered


Purified from tissue culture supernatant in an animal free facility


Protein G


Undiluted at 4°C in the dark